Drug combination shows long-term survival in advanced thymic cancer

https://www.news-medical.net/news/20261113/Drug-combination-shows-long-term-survival-in-advanced-thymic-cancer.aspx Final results from the phase 2 PECATI clinical trial demonstrate encouraging long-term survival outcomes with the combination of lenvatinib and pembrolizumab in patients with previously treated advanced B3-thymoma and thymic carcinoma. The findings, published in the Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer (IASLC), showed after a median follow-up of 24.6 months a median progression-free survival of 22.1 months and median overall survival of 40.2 months.